Supernus Pharmaceuticals Inc (NASDAQ:SUPN)
| 21.88 Delayed Data As of Nov 27 |  +0.55 / +2.58%Today’s Change | 13.12 Today|||52-Week Range 25.82 | -7.76% Year-to-Date |
Latest SUPN News | Press Releases
| Is Supernus Pharmaceuticals (SUPN) a Worthy Stock Now? Nov 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 21.33 |
| Today’s open | 21.39 |
| Day’s range | 21.35 - 21.88 |
| Volume | 7,211 |
| Average volume (3 months) | 477,023 |
| Market cap | $1.2B |
Data as of 12:58pm ET, 11/27/2020
Growth & Valuation
| Earnings growth (last year) | +1.04% |
| Earnings growth (this year) | +15.83% |
| Earnings growth (next 5 years) | -22.60% |
| Revenue growth (last year) | -3.95% |
| P/E ratio | 9.1 |
| Price/Sales | 3.25 |
| Price/Book | 1.93 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VCELVericel Corp | +0.18 | +0.72% |
| KPTIKaryopharm Therapeut... | +0.37 | +2.51% |
| ZGNXZogenix Inc | +0.50 | +2.37% |
| INVAInnoviva Inc | +0.26 | +2.46% |
Data as of 12:59pm ET, 11/27/2020
Financials
| Next reporting date | March 2, 2021 |
| EPS forecast (this quarter) | $0.53 |
| Annual revenue (last year) | $392.8M |
| Annual profit (last year) | $113.1M |
| Net profit margin | 28.79% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Rockville, Maryland |
Forecasts
